The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease
Abstract
The aim of the study was to provide evidence‐based recommendations for the management of early (uncomplicated) Parkinson's disease (PD), based on a review of the literature. Uncomplicated PD refers to patients suffering from the classical motor syndrome of PD only, without treatment‐induced motor complications and without neuropsychiatric or autonomic problems. MEDLINE, Cochrane Library and International Network of Agencies for Health Technology Assessment (INAHTA) database literature searches were conducted. National guidelines were requested from all European Federation of Neurological Societies (EFNS) societies. Non‐European guidelines were searched for using MEDLINE. Part I of the guidelines deals with prevention of disease progression, symptomatic treatment of motor features (parkinsonism), and prevention of motor and neuropsychiatric complications of therapy. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (good practice point) is made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Interventions for preventing falls in elderly people
Gillespie, L. D., Gillespie, W. J., Robertson, M. C., Lamb, S. E., Cumming, R. G., & Rowe, B. H. (2003) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000340 · Cited by 1,422
RetractedAlexander, G. E., Crutcher, M. D., & DeLong, M. R. (1990) · PubMed · Cited by 2,679
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa000827 · Cited by 1,514
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study
Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,401
Self-citationWhat contributes to quality of life in patients with Parkinson's disease?
Schrag, A. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
Self-citationDopamine and the regulation of cognition and attention
Nieoullon, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00011-4 · Cited by 1,131
Depression and Parkinson's disease: a review
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.443 · Cited by 1,111
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
Rodriguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J.-L., Pollak, P., Rehncrona, S., Kulisevsky, J., Albanese, A., Volkmann, J., Hariz, M. I., et al. (2005) · Brain · doi:10.1093/brain/awh571 · Cited by 1,057
Deep brain stimulation for Parkinson’s disease
Benabid, A. L. (2003) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2003.11.001 · Cited by 1,046
A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor
Schuurman, P. R., Bosch, D. A., Bossuyt, P. M. M., Bonsel, G. J., van Someren, E. J. W., de Bie, R. M. A., Merkus, M. P., & Speelman, J. D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420703 · Cited by 1,044
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fenelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,037
TRANSPLANTATION OF EMBRYONIC DOPAMINE NEURONS FOR SEVERE PARKINSON'S DISEASE
Reed, R., Reene, P. A. E. G., Reeze, R. O. E. B., Ei, W., Ouchel, W. I. D. U. M., Ao, R. I. K., Infield, W., Ulver, S. H. C., Rojanowski, J. O. Q. T., Idelberg, D. A. E., et al. (2001) · Cited by 1,001
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Kleiner-Fisman, G., Herzog, J., Fisman, D. N., Tamma, F., Lyons, K. E., Pahwa, R., Lang, A. E., & Deuschl, G. (2006) · Movement Disorders · doi:10.1002/mds.20962 · Cited by 957
Self-citationEffect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Rhythmic auditory stimulation in gait training for Parkinson's disease patients
Thaut, M. H., McIntosh, G. C., Rice, R. R., Miller, R. A., Rathbun, J., & Brault, J. M. (1996) · Movement Disorders · doi:10.1002/mds.870110213 · Cited by 835
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationRandomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 824
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson's disease.
McIntosh, G. C., Brown, S. H., Rice, R. R., & Thaut, M. H. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.22 · Cited by 643
Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling
Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Poncet, M., & Chérif, A. A. (2002) · Neurology · doi:10.1212/wnl.59.3.408 · Cited by 642
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Self-citationThe Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
(1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 615
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Funkiewiez, A. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2002.009803 · Cited by 572
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Baron, M. S., Vitek, J. L., Green, J., Kaneoke, Y., Hashimoto, T., Turner, R. S., Woodard, J. L., Delong, M. R., Bakay, R. A. E., Cole, S. A., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400305 · Cited by 558
Saint-Cyr, J. A. (2000) · Brain · doi:10.1093/brain/123.10.2091 · Cited by 554
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Metman, L. V., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M. M., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5.1323 · Cited by 514
Behavioural disorders, Parkinson's disease and subthalamic stimulation
Houeto, J. L. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.701 · Cited by 500
Multicentre European study of thalamic stimulation in parkinsonian and essential tremor
Limousin, P., Speelman, J. D., Gielen, F., Janssens, M., & collaborators, S. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.3.289 · Cited by 491
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
Koller, W., Pahwa, R., Busenbark, K., Hubble, J., Wilkinson, S., Lang, A., Tuite, P., Sime, E., Lazano, A., Hauser, R., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420304 · Cited by 478
Hirsch, M. A., Toole, T., Maitland, C. G., & Rider, R. A. (2003) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(03)00046-7 · Cited by 455
Physiotherapy versus placebo or no intervention in Parkinson's disease
Tomlinson, C. L., Patel, S., Meek, C., Herd, C. P., Clarke, C. E., Stowe, R., Shah, L., Sackley, C. M., Deane, K. H., Wheatley, K., et al. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002817.pub4 · Cited by 441
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Nyholm, D., Nilsson Remahl, A. I. M., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R., Aquilonius, S. M., & Askmark, H. (2005) · Neurology · doi:10.1212/01.wnl.0000149637.70961.4c · Cited by 432
Low, P. A. (1997) · JAMA · doi:10.1001/jama.1997.03540370036033 · Cited by 425
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine
Jankovic, J., Gilden, J. L., Hiner, B. C., Kaufmann, H., Brown, D. C., Coghlan, C. H., Rubin, M., & Fouad-Tarazi, F. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90230-m · Cited by 396
Mayeux, R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530290076015 · Cited by 383
Meta-analysis of randomised controlled trials
Kelly, C. P. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63834-2 · Cited by 382
Brainin, M., Barnes, M., Baron, J. ‐., Gilhus, N. E., Hughes, R., Selmaj, K., & Waldemar, G. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00867.x · Cited by 375
Burchiel, K. J., Anderson, V. C., Favre, J., & Hammerstad, J. P. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00024 · Cited by 371
Physical activity and the risk of Parkinson disease
Chen, H., Zhang, S. M., Schwarzschild, M. A., Hernán, M. A., & Ascherio, A. (2005) · Neurology · doi:10.1212/01.wnl.0000151960.28687.93 · Cited by 371
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370
Self-citationArdouin, C., Pillon, B., Peiffer, E., Bejjani, P., Limousin, P., Damier, P., Arnulf, I., Benabid, A. L., Agid, Y., & Pollak, P. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199908)46:2<217::aid-ana11>3.0.co;2-z · Cited by 366
Rubinstein, T. C., Giladi, N., & Hausdorff, J. M. (2002) · Movement Disorders · doi:10.1002/mds.10259 · Cited by 365
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Kleiner-Fisman, G., Fisman, D. N., Sime, E., Saint-Cyr, J. A., Lozano, A. M., & Lang, A. E. (2003) · Journal of Neurosurgery · doi:10.3171/jns.2003.99.3.0489 · Cited by 351
Lees, A. J. (1995) · BMJ · doi:10.1136/bmj.311.7020.1602 · Cited by 346
Self-citationAltered serotonin metabolism in depressed patients with Parkinson's disease
Mayeux, R., Stern, Y., Cote, L., & Williams, J. B. W. (1984) · Neurology · doi:10.1212/wnl.34.5.642 · Cited by 343
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland, D. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.708 · Cited by 341
The effect of deprenyl and levodopa on the progression of Parkinson's disease
Olanow, C. W., Hauser, R. A., Gauguster, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., & Esterlitz, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380512 · Cited by 334
Effects of visual and auditory cues on gait in individuals with Parkinson's disease
Suteerawattananon, M., Morris, G. S., Etnyre, B. R., Jankovic, J., & Protas, E. J. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.12.007 · Cited by 330
Stride length regulation in Parkinson's disease: the use of extrinsic, visual cues
Lewis, G. N. (2000) · Brain · doi:10.1093/brain/123.10.2077 · Cited by 330
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15945-x · Cited by 321
Treatments for dysarthria in Parkinson's disease
Pinto, S., Ozsancak, C., Tripoliti, E., Thobois, S., Limousin-Dowsey, P., & Auzou, P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00854-3 · Cited by 315
Deep brain stimulation: Postoperative issues
Deuschl, G., Herzog, J., Kleiner-Fisman, G., Kubu, C., Lozano, A. M., Lyons, K. E., Rodriguez-Oroz, M. C., Tamma, F., Tröster, A. I., Vitek, J. L., et al. (2006) · Movement Disorders · doi:10.1002/mds.20957 · Cited by 313
Self-citationEffect on mood of subthalamic DBS for Parkinson’s disease A consecutive series of 24 patients
Berney, A., Vingerhoets, F., Perrin, A., Guex, P., Villemure, J.-G., Burkhard, P. R., Benkelfat, C., & Ghika, J. (2002) · Neurology · doi:10.1212/01.wnl.0000032756.14298.18 · Cited by 310
Deep brain stimulation: Preoperative issues
Lang, A. E., Houeto, J.-L., Krack, P., Kubu, C., Lyons, K. E., Moro, E., Ondo, W., Pahwa, R., Poewe, W., Tröster, A. I., et al. (2006) · Movement Disorders · doi:10.1002/mds.20955 · Cited by 308
Self-citationBrundin, P. (2000) · Brain · doi:10.1093/brain/123.7.1380 · Cited by 305
Deep brain stimulation is preferable to thalamotomy for tremor suppression
Tasker, R. R. (1998) · Surgical Neurology · doi:10.1016/s0090-3019(97)00459-x · Cited by 303
Kostic, V., Przedborski, S., Flaster, E., & Sternic, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 297
Ondo, W. G., Tintner, R., Dat Voung, K., Lai, D., & Ringholz, G. (2005) · Movement Disorders · doi:10.1002/mds.20474 · Cited by 297
Two‐year follow‐up of subthalamic deep brain stimulation in Parkinson's disease
Herzog, J., Volkmann, J., Krack, P., Kopper, F., Pötter, M., Lorenz, D., Steinbach, M., Klebe, S., Hamel, W., Schrader, B., et al. (2003) · Movement Disorders · doi:10.1002/mds.10518 · Cited by 296
Self-citationDEPRENYL IN PARKINSON'S DISEASE
Lees, A. J., Kohout, L. J., Shaw, K. M., Stern, G. M., Elsworth, J. D., Sandler, M., & Youdim, M. B. H. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90725-5 · Cited by 292
Self-citationKatzenschlager, R., Hughes, A., Evans, A., Manson, A. J., Hoffman, M., Swinn, L., Watt, H., Bhatia, K., Quinn, N., & Lees, A. J. (2005) · Movement Disorders · doi:10.1002/mds.20276 · Cited by 286
Self-citationShannon, K. M., Bennett, J. P., Friedman, J. H., & the Pramipexole Study Group (1997) · Neurology · doi:10.1212/wnl.49.3.724 · Cited by 281
Ropinirole for the treatment of early Parkinson's disease
Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., & Ropinirole Study Group (1997) · Neurology · doi:10.1212/wnl.49.2.393 · Cited by 281
Leone, M. A., Brainin, M., Boon, P., Pugliatti, M., Keindl, M., & Bassetti, C. L. (2013) · European Journal of Neurology · doi:10.1111/ene.12043 · Cited by 280
Frequency of Dementia in Parkinson Disease
Aarsland, D., Tandberg, E., Larsen, J. P., & Cummings, J. L. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550060082020 · Cited by 280
Self-citationIntake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis
Etminan, M., Gill, S. S., & Samii, A. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70097-1 · Cited by 279
COOPER, J. A., SAGAR, H. J., DOHERTY, S. M., JORDAN, N., TIDSWELL, P., & SULLIVAN, E. V. (1992) · Brain · doi:10.1093/brain/115.6.1701 · Cited by 275
Cognitive dysfunction and dementia in Parkinson?s disease
Bosboom, J. L. W., Stoffers, D., & Wolters, E. C. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0168-1 · Cited by 273
Reading, P. J., Luce, A. K., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 272
Ganzini, L. K. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.12.1469 · Cited by 269
Romito, L. M., Raja, M., Daniele, A., Contarino, M. F., Bentivoglio, A. R., Barbier, A., Scerrati, M., & Albanese, A. (2002) · Movement Disorders · doi:10.1002/mds.10265 · Cited by 266
Rochester, L., Hetherington, V., Jones, D., Nieuwboer, A., Willems, A.-M., Kwakkel, G., & Van Wegen, E. (2005) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2004.10.040 · Cited by 265
Long‐term results of bilateral pallidal stimulation in Parkinson's disease
Volkmann, J., Allert, N., Voges, J., Sturm, V., Schnitzler, A., & Freund, H. (2004) · Annals of Neurology · doi:10.1002/ana.20091 · Cited by 261
Anticholinergics for symptomatic management of Parkinson´s disease
Katzenschlager, R., Sampaio, C., Costa, J., & Lees, A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003735 · Cited by 259
Self-citationShoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10191 · Cited by 258
Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: A randomized trial
Esselink, R. A. J., de Bie, R. M. A., de Haan, R. J., Lenders, M. W. P. M., Nijssen, P. C. G., Staal, M. J., Smeding, H. M. M., Schuurman, P. R., Bosch, D. A., & Speelman, J. D. (2004) · Neurology · doi:10.1212/01.wnl.0000103235.12621.c3 · Cited by 254
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišt’ák, P., Ressner, P., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00612.x · Cited by 253
Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
Goetz, C. G., Blasucci, L. M., Leurgans, S., & Pappert, E. J. (2000) · Neurology · doi:10.1212/wnl.55.6.789 · Cited by 249
Hussain, I. F. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.371 · Cited by 247
Transplantation of embryonic porcine mesencephalic tissue in patients with PD
Schumacher, J. M., Ellias, S. A., Palmer, E. P., Kott, H. S., Dinsmore, J., Dempsey, P. K., Fischman, A. J., Thomas, C., Feldman, R. G., Kassissieh, S., et al. (2000) · Neurology · doi:10.1212/wnl.54.5.1042 · Cited by 246
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Thomas, A., Iacono, D., Luciano, A. L., Armellino, K., Iorio, A. D., & ONOFRJ, M. C. (2004) · PubMed Central · Cited by 246
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease
Vitek, J. L., Bakay, R. A. E., Freeman, A., Evatt, M., Green, J., McDonald, W., Haber, M., Barnhart, H., Wahlay, N., Triche, S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10517 · Cited by 243
Ellis, T., de Goede, C. J., Feldman, R. G., Wolters, E. C., Kwakkel, G., & Wagenaar, R. C. (2005) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2004.08.008 · Cited by 242
Trépanier, L. L., Kumar, R., Lozano, A. M., Lang, A. E., & Saint-Cyr, J. A. (2000) · Brain and Cognition · doi:10.1006/brcg.1999.1108 · Cited by 241
Physical therapy and Parkinson's disease: A controlled clinical trial
Comelia, C. L., Stebbins, G. T., Brown-Toms, N., & Goetz, C. G. (1994) · Neurology · doi:10.1212/wnl.44.3_part_1.376 · Cited by 236
Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease
Alegret, M., Junqué, C., Valldeoriola, F., Vendrell, P., Pilleri, M., Rumià, J., & Tolosa, E. (2001) · Archives of Neurology · doi:10.1001/archneur.58.8.1223 · Cited by 236
Self-citationBloem, B. R., Steijns, J. A. G., & Smits-Engelsman, B. C. M. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200302000-00003 · Cited by 236
Amantadine for Levodopa-Induced Dyskinesias: A 1-Year Follow-up Study
Metman, L. V., Del Dotto, P., LePoole, K., Konitsiotis, S., Fang, J., & Chase, T. N. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1383 · Cited by 235
Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease
Block, G., Liss, C., Reines, S., Irr, J., & Nibbelink, D. (1997) · European Neurology · doi:10.1159/000117399 · Cited by 234
Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism
Santamaria, J., Tolosa, E., & Valles, A. (1986) · Neurology · doi:10.1212/wnl.36.8.1130 · Cited by 233
Self-citationRamig, L. O., Countryman, S., O'Brien, C., Hoehn, M., & Thompson, L. (1996) · Neurology · doi:10.1212/wnl.47.6.1496 · Cited by 230
Fregni, F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.027060 · Cited by 226
Extrapyramidal reactions with metoclopramide.
Bateman, D. N., Rawlins, M. D., & Simpson, J. M. (1985) · BMJ · doi:10.1136/bmj.291.6500.930 · Cited by 226
Manson, A. J., Turner, K., & Lees, A. J. (2002) · Movement Disorders · doi:10.1002/mds.10281 · Cited by 226
Self-citationRandomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
Leroi, I., Brandt, J., Reich, S. G., Lyketsos, C. G., Grill, S., Thompson, R., & Marsh, L. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.993 · Cited by 226
The effects of physical therapy in Parkinson's Disease: A research synthesis
Goede, C. J. T. D., Keus, S. H. J., Kwakkel, G., & Wagenaar, R. C. (2001) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2001.22352 · Cited by 225
Colzi, A., Turner, K., & Lees, A. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.5.573 · Cited by 225
Self-citationClozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., & Rascol, O. (2004) · Neurology · doi:10.1212/01.wnl.0000110317.52453.6c · Cited by 224
Self-citationBilateral subthalamotomy in Parkinson's disease: initial and long-term response
Alvarez, L. (2005) · Brain · doi:10.1093/brain/awh397 · Cited by 224
Burn, D. J. (2002) · Movement Disorders · doi:10.1002/mds.10114 · Cited by 223
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
Lieberman, A., Olanow, C. W., Sethi, K., Swanson, P., Waters, C. H., Fahn, S., Hurtig, H., Yahr, M., & the Ropinirole Study Group* (1998) · Neurology · doi:10.1212/wnl.51.4.1057 · Cited by 223
Physiotherapy for Parkinson's disease: a comparison of techniques
Tomlinson, C. L., Herd, C. P., Clarke, C. E., Meek, C., Patel, S., Stowe, R., Deane, K. H., Shah, L., Sackley, C. M., Wheatley, K., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002815.pub2 · Cited by 220
Suicide after successful deep brain stimulation for movement disorders
Burkhard, P. R., Vingerhoets, F. J. G., Berney, A., Bogousslavsky, J., Villemure, J.-G., & Ghika, J. (2004) · Neurology · doi:10.1212/01.wnl.0000145603.48221.b5 · Cited by 219
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
Aarsland, D., Hutchinson, M., & Larsen, J. P. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.949 · Cited by 219
Self-citationDujardin, K., Defebvre, L., Krystkowiak, P., Blond, S., & Destée, A. (2001) · Journal of Neurology · doi:10.1007/s004150170139 · Cited by 218
Østergaard, K., Sunde, N., & Dupont, E. (2002) · Movement Disorders · doi:10.1002/mds.10188 · Cited by 217
Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
Friedman, J. H., & Factor, S. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200003)15:2<309::aid-mds1016>3.0.co;2-p · Cited by 216
Honigfeld, G., Arellano, F. M., Sethi, J., Bianchini, A., & Schein, J. R. (1998) · PubMed · Cited by 216
Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
Friedman, J. H., & Factor, S. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200003)15:2<201::aid-mds1001>3.0.co;2-d · Cited by 214
Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis
Morgante, L., Epifanio, A., Spina, E., Zappia, M., Di Rosa, A. E., Marconi, R., Basile, G., Di Raimondo, G., La Spina, P., & Quattrone, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000136891.17006.ec · Cited by 214
Dorsal subthalamotomy for Parkinson's disease
Alvarez, L., Macias, R., Guridi, J., Lopez, G., Alvarez, E., Maragoto, C., Teijeiro, J., Torres, A., Pavon, N., Rodriguez-Oroz, M. C., et al. (2001) · Movement Disorders · doi:10.1002/1531-8257(200101)16:1<72::aid-mds1019>3.0.co;2-6 · Cited by 213
Symptoms and duration of the prodromal phase in parkinson's disease
Gonera, E. G., Hof, M. V., Berger, H. J. C., van Weel, C., & Horstink, M. W. I. M. (1997) · Movement Disorders · doi:10.1002/mds.870120607 · Cited by 213
Self-citationAndersen, J., Aabro, E., Gulmann, N., Hjelmsted, A., & Pedersen, H. E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1980.tb03028.x · Cited by 211
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., et al. (2006) · Movement Disorders · doi:10.1002/mds.20724 · Cited by 210
Self-citationTreatment of Parkinson's disease: levodopa as the first choice
Katzenschlager, R., & Lees, A. J. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1204-4 · Cited by 209
Self-citationGuttman, M., & International Pramipexole-Bromocriptine Study Group (1997) · Neurology · doi:10.1212/wnl.49.4.1060 · Cited by 209
Kurth, M. C., Adler, C. H., St. Hilaire, M., Singer, C., Waters, C., LeWitt, P., Chernik, D. A., Dorflinger, E. E., & Yoo, K. (1997) · Neurology · doi:10.1212/wnl.48.1.81 · Cited by 205
Olanow, C. W., Fahn, S., Muenter, M., Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J. D., Jankovic, J., et al. (1994) · Movement Disorders · doi:10.1002/mds.870090107 · Cited by 204
Beneficial effects of amantadine onL-dopa-induced dyskinesias in Parkinson's disease
Luginger, E., Wenning, G. K., B�sch, S., & Poewe, W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<873::aid-mds1017>3.0.co;2-i · Cited by 203
Self-citationA Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease
(2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1721 · Cited by 203
Schenkman, M., Cutson, T. M., Kuchibhatla, M., Chandler, J., Pieper, C. F., Ray, L., & Laub, K. C. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb04535.x · Cited by 201
Daniele, A., Albanese, A., Contarino, M. F., Zinzi, P., Barbier, A., Gasparini, F., Romito, L. M. A., Bentivoglio, A. R., & Scerrati, M. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.2.175 · Cited by 200
Psychiatric aspects of Parkinson?s disease: An Update
Schrag, A. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0483-3 · Cited by 200
Koller, W. C., Hutton, J. T., Tolosa, E., Capilldeo, R., & the Carbidopa/Levodopa Study Group (1999) · Neurology · doi:10.1212/wnl.53.5.1012 · Cited by 200
Self-citationOlanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease
Breier, A., Sutton, V. K., Feldman, P. D., Kadam, D. L., Ferchland, I., Wright, P., & Friedman, J. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01392-6 · Cited by 198
Montastruc, J. L., Rascol, O., Senard, J. M., & Rascol, A. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1034 · Cited by 198
Self-citationEPIDEMIOLOGY of PARKINSON'S DISEASE IN FINLAND
MABTRILA, R. J., & RINNE, U. K. (1976) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1976.tb04328.x · Cited by 196
Oscillations of the Human Sensorimotor System as Revealed by Magnetoencephalography
Volkmann, J. (2008) · Movement Disorders · doi:10.1002/mds.870131312 · Cited by 195
Physiotherapy versus placebo or no intervention in Parkinson's disease
Tomlinson, C. L., Patel, S., Meek, C., Clarke, C. E., Stowe, R., Shah, L., Sackley, C., Deane, K. H., Wheatley, K., & Ives, N. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002817 · Cited by 194
Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
Fernandez, H. H., Friedman, J. H., Jacques, C., & Rosenfeld, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199905)14:3<484::aid-mds1016>3.0.co;2-b · Cited by 193
Antidepressant studies in Parkinson's disease: A review and meta‐analysis
Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Katz, I. R., & Stern, M. B. (2005) · Movement Disorders · doi:10.1002/mds.20555 · Cited by 191
Management of Parkinson's disease: An evidence-based review
Lang, A. E., & Lees, A. (2002) · Movement Disorders · doi:10.1002/mds.5554 · Cited by 184
Self-citationBrooks, D. J. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.8.1071 · Cited by 182
Bloem, B. R., Steijns, J. A. G., & Smits-Engelsman, B. C. M. (2003) · PubMed · doi:10.1097/01.wco.0000053580.70044.70 · Cited by 178
Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial
de Bie, R. M., de Haan, R. J., Nijssen, P. C., Rutgers, A. W. F., Beute, G. N., Bosch, D. A., Haaxma, R., Schmand, B., Schuurman, P. R., Staal, M. J., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03556-4 · Cited by 177
Metoclopramide-induced movement disorders. Clinical findings with a review of the literature
Miller, L. G. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.11.2486 · Cited by 177
Deep brain stimulation for Parkinson's disease: Surgical issues
Rezai, A. R., Kopell, B. H., Gross, R. E., Vitek, J. L., Sharan, A. D., Limousin, P., & Benabid, A.-L. (2006) · Movement Disorders · doi:10.1002/mds.20956 · Cited by 176
Snow, B. J., Macdonald, L., Mcauley, D., & Wallis, W. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200003000-00004 · Cited by 174
Olanzapine treatment for dopaminergic‐induced hallucinations
Ondo, W. G., Levy, J. K., Vuong, K. D., Hunter, C., & Jankovic, J. (2002) · Movement Disorders · doi:10.1002/mds.10217 · Cited by 172
Clozapine and Risperidone Treatment of Psychosis in Parkinson's Disease
Ellis, T. D., Cudkowicz, M., Sexton, P., & Growdon, J. H. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.3.364 · Cited by 172
Selegiline as initial treatment in de novo parkinsonian patients
Myllylä, V. V., Sotaniemi, K. A., Vuorinen, J. A., & Heinonen, E. H. (1992) · Neurology · doi:10.1212/wnl.42.2.339 · Cited by 171
Do Atypical Antipsychotics Cause Stroke?
Herrmann, N., & Lanct??t, K. L. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00001 · Cited by 170
Marchese, R., Diverio, M., Zucchi, F., Lentino, C., & Abbruzzese, G. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<879::aid-mds1018>3.0.co;2-9 · Cited by 168
Pogarell, O. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.713 · Cited by 165
Nonmotor complications in Parkinson's disease
Adler, C. H. (2005) · Movement Disorders · doi:10.1002/mds.20460 · Cited by 165
Soykan, I., Sarosiek, I., Shifflett, J., Wooten, G. F., & McCallum, R. W. (1997) · Movement Disorders · doi:10.1002/mds.870120618 · Cited by 164
Ives, N. J., Stowe, R. L., Marro, J., Counsell, C., Macleod, A., Clarke, C. E., Gray, R., & Wheatley, K. (2004) · BMJ · doi:10.1136/bmj.38184.606169.ae · Cited by 164
Herzog, J., Reiff, J., Krack, P., Witt, K., Schrader, B., Müller, D., & Deuschl, G. (2003) · Movement Disorders · doi:10.1002/mds.10530 · Cited by 163
Self-citationLow‐dose L‐dopa therapy in Parkinson's disease: A 6‐year follow‐up study
Poewe, W. H., Lees, A. J., & Stern, G. M. (1986) · Neurology · doi:10.1212/wnl.36.11.1528 · Cited by 163
Self-citationLevodopa‐dyskinesia incidence by age of Parkinson's disease onset
Kumar, N., Van Gerpen, J. A., Bower, J. H., & Ahlskog, J. E. (2005) · Movement Disorders · doi:10.1002/mds.20360 · Cited by 162
Bullock, R., & Cameron, A. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000813 · Cited by 159
Bergman, J., & Lerner, V. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200203000-00009 · Cited by 156
Rehabilitation for Parkinson's disease: a systematic review of available evidence
Gage, H., & Storey, L. (2004) · Clinical Rehabilitation · doi:10.1191/0269215504cr764oa · Cited by 155
Pinter, M. M., Pogarell, O. M., & Oertel, W. H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.4.436 · Cited by 155
Self-citationHely, M. A., Morris, J. G., Reid, W., O'Sullivan, D. J., Williamson, P. M., Rail, D., Broe, G. A., & Margrie, S. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.8.903 · Cited by 154
Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
Fabbrini, G., Barbanti, P., Aurilia, C., Pauletti, C., Lenzi, G. L., & Meco, G. (2002) · Neurological Sciences · doi:10.1007/s100720200022 · Cited by 154
Waters, C., Sethi, K. D., Hauser, R. A., Molho, E., & Bertoni, J. M. (2004) · Movement Disorders · doi:10.1002/mds.20036 · Cited by 153
Cholinesterase inhibition in Parkinson's disease.
Hutchinson, M., & Fazzini, E. P. (1996) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.61.3.324-a · Cited by 150
The Role of Physical Exercise in the Occurrence of Parkinson's Disease
Sasco, A. J., Paffenbarger, R. S., Gendre, I., & Wing, A. L. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530280040020 · Cited by 150
Selegiline delays the onset of disability in de novo parkinsonian patients
Pålhagen, S., Heinonen, E. H., Hägglund, J., Kaugesaar, T., Kontants, H., Mäki-Ikola, O., Palm, R., Turunen, J., & *Swedish Parkinson Study Group (1998) · Neurology · doi:10.1212/wnl.51.2.520 · Cited by 149
Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
Waters, C., Kurth, M., Bailey, P., Shulman, L. M., LeWitt, P. A., Dorflinger, E. E., Deptula, D., Pedder, S. C. J., & the Tolcapone Stable Study Group (1997) · Neurology · doi:10.1212/wnl.49.3.665 · Cited by 149
Long-term follow up of subthalamic nucleus stimulation in Parkinson’s disease
Romito, L. M., Scerrati, M., Contarino, M. F., Bentivoglio, A. R., Tonali, P., & Albanese, A. (2002) · Neurology · doi:10.1212/wnl.58.10.1546 · Cited by 148
Amantadine for dyskinesia in Parkinson's disease
Crosby, N. J., Deane, K. H., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003467 · Cited by 146
Effect of exercise on perceived quality of life of individuals with Parkinson's disease.
Baatile, J., Langbein, W. E., Weaver, F. M., Maloney, C., & Jost, M. B. (2000) · PubMed · Cited by 145
Kurth, M., Tetrud, J. W., Tanner, C. M., Irwin, I., Stebbins, G. T., Goetz, C. G., & Langston, J. (1993) · Neurology · doi:10.1212/wnl.43.9.1698 · Cited by 145
Baas, H. K. J., Beiske, A. G., Ghika, J.-A., Jackson, M., Oertel, W. H., Poewe, W. H., & Ransmayr, G. N. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.4.421 · Cited by 144
Self-citationTrépanier, L. L., Saint‐Cyr, J. A., Lozano, A. M., & Lang, A. E. (1998) · Neurology · doi:10.1212/wnl.51.1.207 · Cited by 143
Ten-year follow-up of three different initial treatments in de-novo PD
Lees, A. J., Katzenschlager, R., Head, J. A., & Ben‐Shlomo, Y. (2001) · Neurology · doi:10.1212/wnl.57.9.1687 · Cited by 143
Self-citationA 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease
Korczyn, A. D., Brunt, E. R., Larsen, J. O., Nagy, Z., Poewe, W. H., & Ruggieri, S. A. (1999) · Neurology · doi:10.1212/wnl.53.2.364 · Cited by 142
Self-citationRisk factors for levodopa-induced dyskinesias in Parkinson's disease
Grandas, F., Galiano, M. L., & Tabernero, C. (1999) · Journal of Neurology · doi:10.1007/s004150050530 · Cited by 142
Mood swings associated with the ‘on—off’ phenomenon in Parkinson's disease
Nissenbaum, H., Quinn, N. P., Brown, R. G., Toone, B., Gotham, A.-M., & MARSDEN, C. D. (1987) · Psychological Medicine · doi:10.1017/s0033291700000702 · Cited by 141
Okabe, S., Ugawa, Y., & Kanazawa, I. (2002) · Movement Disorders · doi:10.1002/mds.10370 · Cited by 140
Adler, C. H., Singer, C., O'Brien, C., Hauser, R. A., Lew, M. F., Marek, K. L., Dorflinger, E., Pedder, S., Deptula, D., & Yoo, K. (1998) · Archives of Neurology · doi:10.1001/archneur.55.8.1089 · Cited by 137
Long‐term outcome of quetiapine use for psychosis among parkinsonian patients
Fernandez, H. H., Trieschmann, M. E., Burke, M. A., Jacques, C., & Friedman, J. H. (2003) · Movement Disorders · doi:10.1002/mds.10374 · Cited by 136
Möller, J. C., Oertel, W., Köster, J., Pezzoli, G., & Provinciali, L. (2005) · Movement Disorders · doi:10.1002/mds.20397 · Cited by 135
Self-citationGoetz, C. G., Leurgans, S. E., & Raman, R. (2002) · Movement Disorders · doi:10.1002/mds.10024 · Cited by 135
Zgaljardic, D. J., Foldi, N. S., & Borod, J. C. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0178-z · Cited by 133
SSRIs in the treatment of depression in Parkinson's disease
Leentjens, A., Vreeling, F., Luijckx, G., & Verhey, F. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.865 · Cited by 132
Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon
Rajput, A. H., Martin, W. R. W., Saint‐Hilaire, M., Dorflinger, E. E., & Pedder, S. C. J. (1998) · Neurology · doi:10.1212/wnl.50.5_suppl_5.s54 · Cited by 132
Cabergoline in the treatment of early parkinson's disease
Rinne, U. K., Bracco, F., Chouza, C., Dupont, E., Gershanik, O. S., Martí-Massó, J. F., Montastruc, J., MARSDEN, C. D., Dubini, A., Orlando, N., et al. (1997) · Neurology · doi:10.1212/wnl.48.2.363 · Cited by 130
Korczyn, A. D., Brooks, D. J., Brunt, E. R., Poewe, W. H., Rascol, O., & Stocchi, F. (1998) · Movement Disorders · doi:10.1002/mds.870130112 · Cited by 130
Self-citationVelocity modulation and rhythmic synchronization of gait in Huntington's disease
Thaut, M. H., Miltner, R., Lange, H. W., Hurt-Thaut, C., & Hoemberg, V. (1999) · Movement Disorders · doi:10.1002/1531-8257(199909)14:5<847::aid-mds1021>3.0.co;2-g · Cited by 128
Cited by
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Self-citationKehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Self-citationRandomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations
Borgohain, R., Szasz, J., Stanzione, P., Meshram, C., Bhatt, M., Chirilineau, D., Stocchi, F., Lucini, V., Giuliani, R., Forrest, E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25751 · Cited by 293
Drug-Induced Urinary Retention: Incidence, Management and Prevention
Verhamme, K. M. C., Sturkenboom, M. C. J. M., Stricker, B. H. C., & Bosch, R. (2008) · Drug Safety · doi:10.2165/00002018-200831050-00002 · Cited by 264
Metadata
- Authors
- Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., Rascol, O., & Sampaio, C.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2006-10-13
- Volume
- 13
- Issue
- 11
- Pages
- 1170-1185
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2155114981
- Cited by
- 297
- References
- 318
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.